Evidence mapPaperPMID 37446913Full record

ReviewMolecules (Basel, Switzerland)2023

Research Methods and New Advances in Drug-Drug Interactions Mediated by Renal Transporters.

Kexin Lin, Xiaorui Kong, Xufeng Tao, Xiaohan Zhai, Linlin Lv, Deshi Dong, Shilei Yang, Yanna Zhu

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kexin LinDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0009-0002-2361-0234
Xiaorui KongDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0009-0004-2544-4932
Xufeng TaoDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0000-0002-4416-2234
Xiaohan ZhaiDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0009-0008-3048-9499
Linlin LvDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0000-0002-8920-2631
Deshi DongDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0000-0003-3266-4314
Shilei YangDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0000-0001-9468-7488
Yanna ZhuDepartment of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.ORCID 0000-0003-2589-2423
Dalian Medical University · CN

Funding

National Natural Science Foundation of China 82003837
6 · The paper itself

Abstract

The kidney is critical in the human body's excretion of drugs and their metabolites. Renal transporters participate in actively secreting substances from the proximal tubular cells and reabsorbing them in the distal renal tubules. They can affect the clearance rates (CLr) of drugs and their metabolites, eventually influence the clinical efficiency and side effects of drugs, and may produce drug-drug interactions (DDIs) of clinical significance. Renal transporters and renal transporter-mediated DDIs have also been studied by many researchers. In this article, the main types of in vitro research models used for the study of renal transporter-mediated DDIs are membrane-based assays, cell-based assays, and the renal slice uptake model. In vivo research models include animal experiments, gene knockout animal models, positron emission tomography (PET) technology, and studies on human beings. In addition, in vitro-in vivo extrapolation (IVIVE), ex vivo kidney perfusion (EVKP) models, and, more recently, biomarker methods and in silico models are included. This article reviews the traditional research methods of renal transporter-mediated DDIs, updates the recent progress in the development of the methods, and then classifies and summarizes the advantages and disadvantages of each method. Through the sorting work conducted in this paper, it will be convenient for researchers at different learning stages to choose the best method for their own research based on their own subject's situation when they are going to study DDIs mediated by renal transporters.

Indexed as

KidneyMembrane Transport ProteinsAnimalsBiological TransportDrug InteractionsHumansMetabolic Clearance RatePharmaceutical PreparationsMembrane Transport ProteinsPharmaceutical Preparationsanalytical toolsdrug–drug interactionsmodelrenal transporter

Identifiers

PMID37446913
PMCPMC10343503
OpenAlexW4383551199

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.